Tandutinib, also known as MLN519, is a type II tyrosine kinase inhibitor with activity against FLT3 (Clark et al, 2004; reviewed in Staudt et al, 2018; Daver et al, 2019). This pathway describes FLT3 mutants that are resistant to tandutinib-mediated inhibition.
Daver, N, Schlenk, RF, Russell, NH, Levis, MJ
Clark, JJ, Cools, J, Curley, DP, Yu, JC, Lokker, NA, Giese, NA, Gilliland, DG
Staudt, D, Murray, HC, McLachlan, T, Alvaro, F, Enjeti, AK, Verrills, NM, Dun, MD
© 2021 Reactome